Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans - PubMed (original) (raw)
. 2016 Nov;25(11):1456-1463.
doi: 10.1158/1055-9965.EPI-16-0373. Epub 2016 Aug 2.
Krishna L Kanchi 1, Bin Gui 2, David E Larson 1, Robert S Fulton 1, William B Isaacs 3, Aldi Kraja 4, Ingrid B Borecki 4, Li Jia 2, Richard K Wilson 1, Elaine R Mardis 1, Adam S Kibel 5
Affiliations
- PMID: 27486019
- PMCID: PMC5093030
- DOI: 10.1158/1055-9965.EPI-16-0373
Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans
Daniel C Koboldt et al. Cancer Epidemiol Biomarkers Prev. 2016 Nov.
Abstract
Background: Common variants have been associated with prostate cancer risk. Unfortunately, few are reproducibly linked to aggressive disease, the phenotype of greatest clinical relevance. One possible explanation is that rare genetic variants underlie a significant proportion of the risk for aggressive disease.
Method: To identify such variants, we performed a two-stage approach using whole-exome sequencing followed by targeted sequencing of 800 genes in 652 aggressive prostate cancer patients and 752 disease-free controls in both African and European Americans. In each population, we tested rare variants for association using two gene-based aggregation tests. We established a study-wide significance threshold of 3.125 × 10-5 to correct for multiple testing.
Results: TET2 in African Americans was associated with aggressive disease, with 24.4% of cases harboring a rare deleterious variant compared with 9.6% of controls (FET P = 1.84 × 10-5, OR = 3.0; SKAT-O P = 2.74 × 10-5). We report 8 additional genes with suggestive evidence of association, including the DNA repair genes PARP2 and MSH6 Finally, we observed an excess of rare truncation variants in 5 genes, including the DNA repair genes MSH6, BRCA1, and BRCA2 This adds to the growing body of evidence that DNA repair pathway defects may influence susceptibility to aggressive prostate cancer.
Conclusions: Our findings suggest that rare variants influence risk of clinically relevant prostate cancer and, if validated, could serve to identify men for screening, prophylaxis, and treatment.
Impact: This study provides evidence that rare variants in TET2 may help identify African American men at increased risk for clinically relevant prostate cancer. Cancer Epidemiol Biomarkers Prev; 25(11); 1456-63. ©2016 AACR.
©2016 American Association for Cancer Research.
Figures
Figure 1
Selection of genes for targeted resequencing. (A) Genes nominated for sequencing by source. (B) Overlap of prostate cancer pathway genes from Acumenta and GeneGo. (C) Overlap of genes from candidate set (known, pathway) and discovery set (rare variant aggregation tests)
Figure 2
Rare variant aggregation test results for 800 genes. Top: Quantile-quantile plots for the African-American (A), European-American (C) and combined (E) sample sets. Bottom: Fraction of samples with at least one rare deleterious variant in each gene in African-American (B), European-American (D) and combined (F) sample sets. Genes with FET p-value <0.01 are marked in red.
Figure 3
Patterns of rare deleterious variants in selected genes. (A) Rare deleterious variants observed in TET2 in African-American cases (top) and controls (bottom). (B) Rare truncating variants observed in BRCA2 in European-American cases (top) and controls (bottom). (C) Rare deleterious variants in PARP2 observed in European-American cases (top) and controls (bottom).
Similar articles
- Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O. Ledet EM, et al. Prostate. 2021 May;81(7):433-439. doi: 10.1002/pros.24123. Epub 2021 Apr 1. Prostate. 2021. PMID: 33792945 Free PMC article. - DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men.
Plym A, Dióssy M, Szallasi Z, Sartor O, Silberstein J, Powell IJ, Rebbeck TR, Penney KL, Mucci LA, Pomerantz MM, Kibel AS. Plym A, et al. JNCI Cancer Spectr. 2021 Dec 27;6(1):pkab097. doi: 10.1093/jncics/pkab097. eCollection 2022 Feb. JNCI Cancer Spectr. 2021. PMID: 35079693 Free PMC article. - Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M. Petrovics G, et al. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12. Prostate Cancer Prostatic Dis. 2019. PMID: 30542053 Free PMC article. - Prostate Cancer Screening in a New Era of Genetics.
Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Cheng HH, et al. Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31. Clin Genitourin Cancer. 2017. PMID: 28697982 Review. - DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. Mateo J, et al. Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31. Eur Urol. 2017. PMID: 27590317 Review.
Cited by
- Recruiting African American Prostate Cancer Survivors for a Population-based Biobank Study.
Li X, Roy S, Damonte J, Park HY, Hoogland AI, Jamison K, Komrokji KR, Yeo CD, Kim Y, Dhillon J, Gudenkauf LM, Oswald LB, Jim HSL, Yamoah K, Pow-Sang JM, Kanetsky PA, Gwede CK, Park JY, Gonzalez BD. Li X, et al. Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):768-775. doi: 10.1158/1055-9965.EPI-22-1157. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 36958853 Free PMC article. - Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.
Wang A, Xu Y, Yu Y, Nead KT, Kim T, Xu K, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Gapstur SM, Stevens V, Albanes D, Weinstein SJ, Gnanapragasam V, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz MM, Schmidt JA, Stopsack KH, Mucci LA, Catalona WJ, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Kote-Jarai Z, de Smith AJ, Conti DV, Huff C, Haiman CA, Darst BF. Wang A, et al. Hum Mol Genet. 2023 Jan 13;32(3):489-495. doi: 10.1093/hmg/ddac214. Hum Mol Genet. 2023. PMID: 36018819 Free PMC article. - Molecular Features in Lymphatic Metastases Reflect the Metastasis Mechanism of Lymph Nodes With Non-Small-Cell Lung Cancers.
Guo N, Chen Y, Jing Z, Liu S, Su J, Li R, Duan X, Chen Z, Chen P, Yin R, Li S, Tang J. Guo N, et al. Front Bioeng Biotechnol. 2022 Jul 18;10:909388. doi: 10.3389/fbioe.2022.909388. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35923575 Free PMC article. - Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations.
Guan Z, Shen R, Begg CB. Guan Z, et al. Hum Hered. 2021;86(1-4):34-44. doi: 10.1159/000519355. Epub 2021 Oct 29. Hum Hered. 2021. PMID: 34718237 Free PMC article. - TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX, Hollingshead M, Rubinstein L, Nguyen D, Larenjeira ABA, Kinders RJ, Difilippantonio M, Doroshow JH. Yang SX, et al. J Hematol Oncol. 2021 May 26;14(1):83. doi: 10.1186/s13045-021-01091-5. J Hematol Oncol. 2021. PMID: 34039392 Free PMC article.
References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66:7–30. - PubMed
- Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol. 1992;23:211–22. - PubMed
- Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine. 2009;360:1320–8. - PubMed
- Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute. 2002;94:981–90. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous